Tekla Capital Management LLC Sutro Biopharma, Inc. Transaction History

Tekla Capital Management LLC

$2.53 Billion
Q2 2023

A detailed history of Tekla Capital Management LLC transactions in Sutro Biopharma, Inc. stock. As of the latest transaction made, Tekla Capital Management LLC holds 98,354 shares of STRO stock, worth $176,053. This represents 0.02% of its overall portfolio holdings.

Number of Shares

98,354

Previous 98,354 -0.0%

Holding current value

$176,053

Previous $454,000 0.66%

% of portfolio

0.02%

Previous 0.02%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	SELL	$4.48 - $8.45 $220,312 - $415,545	-49,177 Reduced 33.33%	98,354 $454,000
Q4 2022 Feb 10, 2023	SELL	$5.41 - $8.08 $88,686 - $132,455	-16,393 Reduced 10.0%	147,531 $1.19 Million
Q1 2022 May 13, 2022	SELL	$7.78 - $15.31 $1.28 Million - $2.51 Million	-163,926 Reduced 50.0%	163,924 $1.35 Million
Q4 2021 Feb 14, 2022	SELL	$14.25 - $23.53 $1.03 Million - $1.7 Million	-72,297 Reduced 18.07%	327,850 $4.88 Million
Q2 2021 Aug 13, 2021	SELL	$18.03 - $23.82 $3.13 Million - $4.14 Million	-173,676 Reduced 30.27%	400,147 $7.44 Million
Q1 2021 May 14, 2021	SELL	$20.29 - $27.54 $2.61 Million - $3.54 Million	-128,700 Reduced 18.32%	573,823 $13.1 Million
Q4 2020 Feb 12, 2021	BUY	$10.16 - $23.98 $622,350 - $1.47 Million	61,255 Added 9.55%	702,523 $15.3 Million
Q1 2019 May 14, 2019	BUY	$8.8 - $11.87 $3.62 Million - $4.88 Million	411,368 Added 178.93%	641,268 $7.3 Million
Q4 2018 Feb 13, 2019	SELL	$8.69 - $14.85 $174,669 - $298,485	-20,100 Reduced 8.04%	229,900 $2.07 Million
Q3 2018 Nov 13, 2018	BUY	$15.0 - $15.2 $3.75 Million - $3.8 Million	250,000 New	250,000 $3.75 Million

Others Institutions Holding STRO

# of Institutions

132

Shares Held

63.1M

Call Options Held

205K

Put Options Held

28.1K

View Full List

About SUTRO BIOPHARMA, INC.

Ticker STRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,161,500
Market Cap $93.4M
Description
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-dr...

More about STRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tekla Capital Management LLC with notifications on news.

Account

Tekla Capital Management LLC Sutro Biopharma, Inc. Transaction History